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Risk factors for venous thromboembolism
in patients with lymphoma requiring
hospitalization
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Lymphoma is among the malignancies at high risk of
venous thromboembolism (VTE)1. The VTE risk is the
highest upfront during the ﬁrst month after lymphoma
diagnosis and decreases over time2. This upfront risk may
be related to tumor burden and start of chemotherapy as
contributing factors.
Routine assessment of thrombosis risk is recommended
for patients with newly diagnosed neoplastic diseases3.
Khorana et al developed a risk model for predicting
chemotherapy-associated VTE based on baseline clinical
and laboratory variables; however, only a minority of
patients (12.6%) in the study cohort had lymphomas1.
Several studies indicate a higher VTE risk in patients with
aggressive non-Hodgkin lymphomas (NHL)2,4–8,
advanced stage disease (III/IV)2, localization in the central
nervous system (CNS)9, and use of anthracyclines2. The
incidence of VTE during chemotherapy in NHL patients
was investigated analyzing the databases of 12 Italian
clinical trials, identifying DLBCL histology and Khorana
score as risk factors8. A recent monocentric study iden-
tiﬁed mediastinal involvement, BMI > 30 kg/m2, reduced
mobility, extranodal localization, development of neu-
tropenia and hemoglobin level < 100 g/L as VTE risk
factors in patients who had received at least one che-
motherapy cycle10.
However, the inclusion criteria adopted in some of the
aforementioned studies can produce an underestimation
of the risk. Deriving risk scores from clinical trials and/or
out-patient populations could produce results not tailored
for lymphoma patients more prone to VTE because of a
poorer clinical condition as suggested by the need for
hospitalization. Hospitalization, in turn, is a risk factor for
VTE in general and in cancer patients in particular11,12.
The aim of our study was to determine the incidence of
VTE and to identify lymphoma-speciﬁc risk factors. We
chose to investigate those patients with at least one hos-
pital stay during the period of initial staging or subsequent
therapy, in order to address this issue in a population with
a reduced risk dilution.
Our study is a monocentric retrospective analysis of 857
adult patients with newly diagnosed lymphomas con-
secutively admitted and treated in our center from 2004 to
2015, and having had at least one hospital stay. The study
was approved by our institutional review board. All
patients provided written consent.
Diagnoses included the following: Diffuse large B cell
lymphoma (DLBCL), n= 438; Hodgkin lymphoma (HL),
n= 192; Follicular lymphoma (FL), n= 80; Peripheral T-
cell lymphoma (PTCL), n= 61; Mantle cell lymphoma
(MCL), n= 53; Primary CNS lymphoma (PCNSL), n= 33.
DLBCL, PTCL, and MCL were labeled as aggressive
lymphomas. Median age was 57 years (range 18–90).
Other patient characteristics are shown in Table 1.
We recorded all ﬁrst objectively diagnosed deep vein
thromboses (DVT) and/or pulmonary embolisms (PE).
Thrombosis of superﬁcial veins (n= 2) and of arteries (n
= 8) was not considered an event of interest. Diagnosis of
VTE was accepted only if it was conﬁrmed by objective
methods. VTE was classiﬁed as symptomatic when DVT
and/or PE were associated with clinical signs or symp-
toms, and as incidental when routine imaging for disease
evaluation revealed clinically asymptomatic events.
VTE was registered as heralding when was present at
diagnosis before the start of treatment, and as treatment-
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related, when occurred during the ﬁrst-line therapy in a
time interval up to 9 months from the ﬁrst cycle (i.e., in a
time frame in which the ﬁrst-line regimens consisting of
6–8 cycles of chemotherapy are usually completed).
Patients were followed from the time of diagnosis until
the development of VTE, death, or loss to follow-up,
whichever came ﬁrst. The cumulative incidence of VTE
was calculated from diagnosis according to the
Kaplan–Meier method. VTE present at diagnosis were
recorded as time 0. Risk factors for VTE were analyzed by
univariate and multivariate analysis; a ROC analysis
identiﬁed optimal cutoff points for continuous variables.
In the competing risk analysis, we censored patients at the
time of death. Competing-risk regression was based on
Fine and Gray’s proportional subdistribution hazards
model13. All tests were two-sided and P values < 0.05 were
considered as signiﬁcant. Statistical analyses were per-
formed using the STATA 12 software (STATACORP,
College Station, TX, USA).
Seventy-ﬁve patients did not complete the 9 months
period and were censored at the time of last observation.
During the entire observation period of 12,093 months
(median 14 months per patient, range 6-15 months), 95
VTE events were observed. This corresponds to an overall
rate of 11.1% (95/857); 18 patients had PE, that was
isolated in 10 cases, and 11 had splanchnic venous
thrombosis. In 54 patients, VTE was present at diagnosis
or occurred until the ﬁrst cycle of therapy, while in 41
VTE occurred during the ﬁrst-line therapy. VTE was
symptomatic in 57/95 patients (60%); heralding and
treatment-related VTE were symptomatic in 35/54
(64.8%) and 22/41 (53.6%) patients, respectively (p=
0.29).
VTE rate differed with histology. PCNSL had a VTE
peak incidence in PCNSL (9/33, 27.2%); further, the VTE
rate was signiﬁcantly higher in aggressive lymphomas
(DLBCL= 12.6%, 55/438; PTCL 13.1%, 8/61; MCL 11.3%,
6/53; overall 13.3%, 78/585) than in HL (6.8%, 13/192), or
FL (5%, 4/80) (overall 6.2%, 17/272) (p= 0.01). In the
univariate analysis, age > 60 years, ECOG ≥ 2, aggressive
histology, PCNSL, bulky disease > 10 cm, albumin levels ≤
4.0 g/dL, and elevated LDH levels resulted signiﬁcantly
associated with VTE (Table 1).
The multivariate logistic regression analysis included
only the factors with signiﬁcance at the univariate analy-
sis; ECOG ≥ 2, bulky disease > 10 cm, and PCNSL retained
their signiﬁcance as VTE risk factors (Table 1).
All characteristics that we identiﬁed as VTE risk factors
with the exception of age were conﬁrmed as risk factors
for symptomatic VTE (Table 1). Most importantly, the
Table 1 Patient characteristics and VTE risk
All VTE Symptomatic VTE
Parameter Number of
patients
Univariate analysis Multivariate analysis Univariate Analysis Multivariate Analysis
OR 95% CI P value OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age > 60 years (n= 857) 384 (44.8%) 1.61 1.05–2.49 0.03 1.12 0.70–1.90 0.7 1.71 0.99–2.95 0.06
Male gender (n= 857) 431 (50.3%) 1.05 0.69–1.61 0.8 1.19 0.70–2.04 0.5
Aggressive histologya
(n= 857)
585 (68.3%) 2.17 1.23–3.72 0.007 0.74 0.53–1.03 0.08 2.61 1.26–5.40 0.01 1.10 0.47–2.60 0.8
PCNSL (n= 857) 33 (3.9%) 3.22 1.45–7.15 0.004 3.70 1.41–9.69 0.008 5.06 2.17–11.2 < 0.001 6.32 2.21–18.2
Stage, III–IV (n= 849) 537 (63.2%) 1.34 0.84–2.13 0.2 0.89 0.51–1.55 0.7
Bulk > 10 cm (n= 849) 208 (24.5%) 2.67 1.71–4.15 0.001 3.23 1.85–5.63 0.0001 2.04 1.17–3.58 0.01 2.84 1.42–5.72 0.003
ECOG ≥ 2 (n= 849) 270 (31.8 %) 3.28 2.10–5.10 0.001 1.80 1.03–3.13 0.04 4.26 2.39–7.60 < 0.001 2.56 1.28–5.11 0.008
WBC > 11 × 109/l (n= 831) 179 (21.5%) 1.31 0.80–2.15 0.3 1.70 0.93–3.08 0.08
Plt > 350 × 109/l (n= 832) 233 (28%) 0.83 0.50–1.36 0.5 0.48 0.23–1.0 0.05
Hb < 10 g/dl (n= 839) 147 (17.5%) 1.06 0.61–1.85 0.8 1.34 0.70–2.61 0.4
Albumin < 4 g/dl (n= 736) 417 (56.7%) 2.5 1.45–4.30 0.001 1.74 0.95–3.19 0.07 2.27 1.16–4.46 0.02 1.31 0.62–2.79 0.4
LDH elevated > UNV
(n= 835)
314 (37.6%) 2.30 1.49–3.58 0.001 1.07 0.62–1.86 0.8 2.03 1.42–3.51 0.01 1.34 0.66–2.71 0.5
P values < 0.05 are shown in bold
Multivariate logistic regression analysis included 717 patients
OR odds ratio, PCNSL primary central nervous system lymphoma, WBC white blood cell count, Plt platelet count, Hb hemoglobin, UNV upper normal value
aAggressive histology includes diffuse large B cell lymphoma, mantle cell lymphoma and peripheral T-cell lymphoma; follicular lymphoma and Hodgkin lymphoma
were considered non-aggressive histology
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multivariate analysis identiﬁed the same three risk factors
(ECOG ≥ 2, bulky disease > 10 cm, and PCNSL) as risk
factors for symptomatic VTE (Table 1).
Only a minority of patients (16%), in particular, those >
60 years and with a reduced performance status did not
receive anthracyclines. Even after adjustment for such
covariates, no association between use of doxorubicin and
VTE was observed (data not shown).
We next grouped patients to the presence of risk fac-
tors. PCNSL patients had the highest VTE rate (27.2%).
Patients with reduced performance status (ECOG ≥ 2) or
bulky disease (>10 cm diameter) had a very similar VTE
risk (53/270, 19.6% and 41/208, 19.7%, respectively), and
were therefore grouped together in a group termed “bulk
and/or ECOG” (69/377, 18.3%). The VTE rate in patients
without these risk factors (n= 447) was 3.8%. The rate of
symptomatic VTE was similar in the three risk groups
(24.2% in PCNSL, 11.1% in the bulk and/or ECOG group,
and 1.6% in the low-risk group). Figure 1 shows the risk
over time in a competing-risk model. The curves suggest
that the VTE risk factors are valid both for VTE events at
diagnosis and during therapy.
An analysis focusing on patients with score 0 did not
identify a risk factor possibly discerning patients at lowest
risk (data not shown).
In conclusion, we identiﬁed VTE risk factors in patients
with lymphoma that are well different from VTE risk
factors described for solid tumors. We identiﬁed three
main clinical risk factors: CNS localization, tumor bulk >
10 cm and reduced performance status. We conﬁrm
aggressive lymphoma histology as VTE risk factor in
univariate, but not in multivariate analysis.
Bulk and reduced ECOG probably contribute to slowing
down the blood ﬂow in the venous bed. In fact, analyzing
for associations between localization of VTE and risk
factors, we found an association between the site of the
bulk and thrombosis (data not shown). A reduction of the
performance status to the ECOG grade 2 or greater that
deﬁnes a reduction of the daily activity with variation
from partial to complete immobilization was associated
with a higher VTE localization to the lower extremities.
Analyzing for laboratory abnormalities, we found lower
albumin and elevated LDH levels at diagnosis to be
associated with VTE. LDH is a proliferation marker
typically elevated in aggressive lymphomas. Low albumin
levels may be due to an altered nutritional status or an
inﬂammatory environment reducing albumin production
and may lead to endothelial cell activation increasing the
thrombotic risk14. Other laboratory abnormalities, in
particular, the CBC counts that are an essential part of the
Khorana score, did not prove to be signiﬁcant in lym-
phoma patients.
Comparison with other studies8,10 is difﬁcult because of
differences in patient selection. Our study cohort is a real-
life case series including both HL and NHL, including also
VTE that was present before the start of therapy. This is
well justiﬁed as the recent analysis of a Swedish registry of
40,354 NHL patients showed that the incidence of
thrombosis started to increase about ﬁve months before
diagnosis, and reached its peak a month before diag-
nosis15. We included only patients with at least one hos-
pital stay. Patients as those with low-grade histology who
did not require a hospital stay were not retrieved. As
expected, this may explain the higher incidence rate of
VTE with respect to other reports1,2,8,10. Therefore, our
study tackles the issue of VTE frequency in a population
at increased risk, in whom special care is required and
speciﬁc information are needed.
In summary, we identiﬁed lymphoma-speciﬁc VTE risk
factors that could be useful tools to plan tailored antith-
rombotic prophylaxis.
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Fig. 1 Cumulative incidence rates of VTE. The graph shows the
results of a competing risk regression analysis. Death was counted as a
competitive event. VTE before the start of systemic therapy were
considered heralding events and were counted as events at time 0,
while VTE during the ﬁrst nine months from treatment start was
considered treatment-related events. Subdistribution hazard risk was
5.2-fold (95% CI, 3.1–8.8) for patients with the risk factors reduced
performance status (ECOG > 2) and/or bulky disease (>10 cm), and 8.0-
fold (95% C.I., 3.7–17.5) for patients with PCNSL.Analysis of the
treatment-related VTE in 803 patients, after exclusion of the 54 ones
who presented with VTE before the start of therapy, conﬁrmed a VTE
risk gradient similar to that of the overall cohort (see text) (5/29, 17.2%
in PCNSL, 25/333, 7.5% in the bulk and/or ECOG group, and 11/441,
2.5% in the low-risk group)
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